Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of irinotecan, cetuximab and everolimus in chemotherapy-resistant metastatic colorectal cancer
2009-015952-11Phase 2Completed
- Sponsor
- Herlev Hospital
- Start
- Oct 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan, cetuximab and everolimus in metastatic colorectal adenocarcinoma (mCRC), sponsored by Herlev Hospital. Primary endpoints: Disease control rate and Time to progression (TTP). Started Oct 2009; status: completed.
02
Drugs
irinotecancetuximabeverolimus
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-015952-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015952-11.